Aflac (AFL) Expected to Announce Earnings on Wednesday

Aflac (NYSE:AFL - Get Free Report) is anticipated to announce its Q1 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of $1.69 per share and revenue of $4.53 billion for the quarter.

Aflac (NYSE:AFL - Get Free Report) last issued its earnings results on Wednesday, February 5th. The financial services provider reported $1.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.63 by ($0.07). Aflac had a return on equity of 16.20% and a net margin of 28.76%. On average, analysts expect Aflac to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Aflac Stock Performance

Shares of AFL stock opened at $108.28 on Wednesday. The stock has a 50-day moving average of $106.84 and a 200-day moving average of $107.17. Aflac has a one year low of $80.59 and a one year high of $115.50. The stock has a market cap of $59.10 billion, a PE ratio of 11.28, a price-to-earnings-growth ratio of 3.24 and a beta of 0.81. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.10 and a quick ratio of 0.08.

Insider Activity at Aflac

In other news, Director Joseph L. Moskowitz sold 1,000 shares of Aflac stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the director now owns 25,393 shares of the company's stock, valued at $2,733,048.59. This trade represents a 3.79 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Charles D. Lake II sold 29,802 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $107.29, for a total transaction of $3,197,456.58. Following the completion of the sale, the director now directly owns 49,962 shares in the company, valued at approximately $5,360,422.98. The trade was a 37.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.90% of the company's stock.

Hedge Funds Weigh In On Aflac

A hedge fund recently raised its stake in Aflac stock. Brighton Jones LLC grew its holdings in shares of Aflac Incorporated (NYSE:AFL - Free Report) by 64.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,570 shares of the financial services provider's stock after purchasing an additional 5,708 shares during the period. Brighton Jones LLC's holdings in Aflac were worth $1,507,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 67.44% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Piper Sandler boosted their price target on shares of Aflac from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Wednesday, April 2nd. UBS Group raised their price target on Aflac from $109.00 to $114.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 2nd. Morgan Stanley decreased their price objective on Aflac from $105.00 to $100.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. StockNews.com upgraded shares of Aflac from a "sell" rating to a "hold" rating in a report on Friday, February 14th. Finally, BMO Capital Markets initiated coverage on shares of Aflac in a report on Thursday, January 23rd. They issued a "market perform" rating and a $111.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $103.93.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.